Drug Type Universal CAR-T |
Synonyms 4SCAR7U |
Target |
Action modulators |
Mechanism CD7 modulators(T-cell antigen CD7 modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia | Phase 1 | China | 31 Oct 2023 | |
| CD7 positive Hematologic Neoplasms | Phase 1 | China | 31 Oct 2023 | |
| CD7 Positive Neoplasms | Phase 1 | China | 31 Oct 2023 | |
| NK-cell lymphoma | Phase 1 | China | 31 Oct 2023 | |
| Precursor T-cell lymphoblastic lymphoma | Phase 1 | China | 31 Oct 2023 |





